Heading into this year's flu season, vaccinemakers were hoping to follow up the top-line success they scored last year with quadrivalent rollouts. But with this year's vaccines registering a paltry 23% effectiveness rate this season thanks to a mutated strain, it might be time to make some changes.
BioCryst Pharmaceuticals won its first-ever FDA approval for a new treatment and subsequently saw its shares slide as analysts yawned over its sales potential.
Last year, Sanofi's fourth-quarter flu vaccine sales soared on the introduction of a quadrivalent contender, surging more than 94%. Now, looking to keep that growth coming, the company is adding another four-strain shot to the mix.
After last week partially banning Novartis' Fluad, Italian officials now say tests on the flu vaccine show the product is safe.
Flu shots are a driving sales force for more than a couple vaccine players. But could an oral alternative disrupt the flu vaccine market down the line?
To help show Americans just how important its flu vaccines are, Novartis has teamed up with entertainer Nick Cannon, who's advising consumers to prepare for flu season by getting their shots and stocking up on the Swiss pharma's over-the-counter remedy, Theraflu.
Inovio Pharmaceuticals, AstraZeneca's MedImmune and the University of Pennsylvania have joined forces to study influenza and antibiotic-resistant bacteria, drawing on $12.2 million in federal funds.
As it works to refine its vaccine strategy for the event of an avian flu pandemic, the NIH is trialing Sanofi's H7N9 vaccine at a range of doses and with a variety of adjuvant combinations. And now, it has one that looks promising.
In the years since the H1N1 pandemic, pharmacies have established themselves as major providers of vaccines, with Walgreens and CVS administering jabs to more than 10 million people last year. But while anything that makes it easier for patients to get vaccinated is welcomed by public health officials and manufacturers, physicians have reservations about pharmacies stepping onto their turf.
To get the word out on AstraZeneca's needle-free FluMist Quadrivalent vaccine, the company has brought on James Van Der Beek--of "Dawson's Creek" fame--to participate in its "Insist on the Mist" campaign.